Revolution Medicines (RVMD) Equity Ratio (2019 - 2026)

Revolution Medicines has reported Equity Ratio for 8 years, with the latest figure at 0.67 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 24.25% year-over-year to 0.67; the trailing twelve-month figure through Mar 2026 stood at 0.67 (down 24.25% YoY), and the FY2025 full-year result was 0.69, down 21.75% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.67, down from 0.69 in the prior quarter.
• The five-year high for Equity Ratio was 0.9 in Q1 2024, with the low at 0.67 in Q1 2026.
• Average Equity Ratio over 5 years is 0.83, with a median of 0.85 recorded in 2023.
• Year-over-year, Equity Ratio advanced 9.97% in 2023 and retreated 24.25% in 2026.
• Tracing RVMD's Equity Ratio over 5 years: stood at 0.84 in 2022, then grew by 4.96% to 0.89 in 2023, then retreated by 0.04% to 0.89 in 2024, then decreased by 21.75% to 0.69 in 2025, then retreated by 3.94% to 0.67 in 2026.
• The last three Equity Ratio figures came in at 0.67 (Q1 2026), 0.69 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.

Peer Comparison